Mar 14 |
ProQR Therapeutics Full Year 2023 Earnings: Misses Expectations
|
Mar 13 |
ProQR reports FY results
|
Mar 13 |
ProQR Announces Year End 2023 Operating and Financial Results
|
Jan 19 |
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
|
Jan 18 |
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Jan 15 |
While institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the most
|
Jan 5 |
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
|
Dec 28 |
Is ProQR (PRQR) Stock a Solid Choice Right Now?
|
Dec 8 |
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
|
Nov 7 |
ProQR GAAP EPS of -€0.07, revenue of €1.37M
|